{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:19:08Z","timestamp":1790255948517,"version":"4.1.0"},"reference-count":117,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/coc.0000000000000023","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T15:17:29Z","timestamp":1387379849000},"page":"76-84","source":"Crossref","is-referenced-by-count":31,"title":["Off-Target Effects of BCR-ABL and JAK2 Inhibitors"],"prefix":"10.1097","volume":"39","author":[{"given":"Myke R.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Fancher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R2-13-20210128","first-page":"1S29","article-title":"Lessons learned from the development of imatinib.","volume":"28suppl","author":"Lydon","year":"2004","journal-title":"Leuk Res"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":". Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nchembio.1085","article-title":". Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.","volume":"8","author":"Winter","year":"2012","journal-title":"Nat Chem Biol"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14656566.2011.533169","article-title":"Treatment of chronic myeloid leukemia when imatinib fails.","volume":"12","author":"Hehlmann","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":". Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":". Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":". A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction.","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The ins and outs of Bcr-Abl inhibition.","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":". Preclinical characterization of the selective JAK12 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":". Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":". The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.bmc.2010.01.056","article-title":"Colony stimulating factor-1 receptor as a target for small molecule inhibitors.","volume":"18","author":"Mashkani","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":". Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":". AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":". Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":". Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":". Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual SrcAbl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":". The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":". In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl neoplastic cells.","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"R26-13-20210128","first-page":"375","article-title":". SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":". Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS One"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":". AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"OHare","year":"2009","journal-title":"Cancer Cell"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":". Discovery of 3-2-(imidazo1,2-bpyridazin-3-yl)ethynyl-4-methyl-N-4-(4-methylpiperazin-1-y l)methyl-3-(trifluoromethyl)phenylbenzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/leu.2009.228","article-title":". A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.","volume":"24","author":"Rix","year":"2010","journal-title":"Leukemia"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/jm200326p","article-title":". Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo19.3.1.1(2,6). 1(8,12)heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2fms-like tyrosine kinase-3 (JAK2FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.","volume":"54","author":"William","year":"2011","journal-title":"J Med Chem"},{"key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1038\/sj.onc.1203698","article-title":". Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.","volume":"19","author":"Wang","year":"2000","journal-title":"Oncogene"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":". CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1568009013334250","article-title":"The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.","volume":"1","author":"ODwyer","year":"2001","journal-title":"Curr Cancer Drug Targets"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":". Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":". A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"key":"R39-13-20210128","first-page":"2395","article-title":". Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).","volume":"59","author":"George","year":"1999","journal-title":"Cancer Res"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":". Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.","volume":"44","author":"Boschelli","year":"2001","journal-title":"J Med Chem"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":". NS-187, a potent and selective dual Bcr-AblLyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1535-6108(02)00080-6","article-title":"Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.","volume":"1","author":"Sawyers","year":"2002","journal-title":"Cancer Cell"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":". Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk Res"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","article-title":". INNO-406, a novel BCR-ABLLyn dual tyrosine kinase inhibitor, suppresses the growth of Ph leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.","volume":"109","author":"Yokota","year":"2007","journal-title":"Blood"},{"key":"R45-13-20210128","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":". Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.","volume":"86","author":"OBrien","year":"1995","journal-title":"Blood"},{"key":"R46-13-20210128","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","article-title":". Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.","volume":"93","author":"OBrien","year":"1999","journal-title":"Blood"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","article-title":"Inhibition of translation in eukaryotic systems by harringtonine.","volume":"72","author":"Fresno","year":"1977","journal-title":"Eur J Biochem"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.12.2.298","article-title":"Cytotoxicity and cell cycle specificity of homoharringtonine.","volume":"12","author":"Baaske","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12185-008-0081-8","article-title":". Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.","volume":"87","author":"Kuroda","year":"2008","journal-title":"Int J Hematol"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/leu.2011.380","article-title":". Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common beta-subunit c of cytokine receptors.","volume":"26","author":"Klag","year":"2012","journal-title":"Leukemia"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":". Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stemprogenitor cells.","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia"},{"key":"R53-13-20210128","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":". Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"R54-13-20210128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":". Therapeutic targeting of Janus kinases.","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"R55-13-20210128","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":". Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","article-title":". Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action.","volume":"79","author":"Miller","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":". Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS One"},{"key":"R58-13-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors.","volume":"9","author":"Grimminger","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R59-13-20210128","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1158\/1078-0432.CCR-11-3359","article-title":". Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.","volume":"18","author":"Chan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R60-13-20210128","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1078-0432.CCR-11-2486","article-title":". Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.","volume":"18","author":"Wheeler","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R61-13-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":". Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro-oncology"},{"key":"R62-13-20210128","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/annonc\/mdq757","article-title":". Src: a potential target for the treatment of triple-negative breast cancer.","volume":"22","author":"Tryfonopoulos","year":"2011","journal-title":"Ann Oncol"},{"key":"R63-13-20210128","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":". Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"R64-13-20210128","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","article-title":". Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves ophthalmopathy.","volume":"50","author":"van Steensel","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R65-13-20210128","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":". Src inhibition ameliorates polycystic kidney disease.","volume":"19","author":"Sweeney","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R66-13-20210128","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":". Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R67-13-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":". Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R68-13-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","article-title":". Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.","volume":"10","author":"Napier","year":"2011","journal-title":"Cell Host Microbe"},{"key":"R69-13-20210128","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":". Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"R70-13-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm1265","article-title":". Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.","volume":"11","author":"Reeves","year":"2005","journal-title":"Nat Med"},{"key":"R71-13-20210128","first-page":"481","article-title":"Molecular alterations underlying eosinophilic and mast cell malignancies.","volume":"12","author":"Sadrzadeh","year":"2011","journal-title":"Discov Med"},{"key":"R72-13-20210128","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":". A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"R73-13-20210128","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":". The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"R74-13-20210128","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.leukres.2008.12.001","article-title":"Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.","volume":"33","author":"Butterfield","year":"2009","journal-title":"Leuk Res"},{"key":"R75-13-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":". Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease.","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"R76-13-20210128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":". Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"R77-13-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":". Imatinib for refractory chronic graft-versus-host disease with fibrotic features.","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"R78-13-20210128","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bmt.2009.368","article-title":". Development of severe sclerotic chronic GVHD during treatment with dasatinib.","volume":"45","author":"Pulanic","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R79-13-20210128","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","article-title":"Molecular pathobiology of gastrointestinal stromal sarcomas.","volume":"3","author":"Corless","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"R80-13-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00160313","article-title":". Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains.","volume":"41","author":"Rousset","year":"1995","journal-title":"J Mol Evol"},{"key":"R81-13-20210128","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":". Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factorkit-ligand in long-term culture.","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"R82-13-20210128","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":". Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"R83-13-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PPO.0b013e31824b2404","article-title":"Therapeutic implications of KIT in melanoma.","volume":"18","author":"Postow","year":"2012","journal-title":"Cancer J"},{"key":"R84-13-20210128","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":". KIT as a therapeutic target in metastatic melanoma.","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R85-13-20210128","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":". Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R86-13-20210128","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-09-0459","article-title":". Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.","volume":"8","author":"Woodman","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R87-13-20210128","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1517\/13543784.2012.679341","article-title":"A potential role for nilotinib in KIT-mutated melanoma.","volume":"21","author":"Tran","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"R88-13-20210128","first-page":"1i48","article-title":"Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.","volume":"69suppl","author":"Distler","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R89-13-20210128","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":". Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R90-13-20210128","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":". Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"R91-13-20210128","first-page":"e691","article-title":"Rota-Scalabrini D, et al..","volume":"29","author":"Carnevale-Schianca","year":"2011","journal-title":"Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkins lymphoma: hope for severe chemotherapy-induced toxicity J Clin Oncol"},{"key":"R92-13-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":". Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J Exp Med"},{"key":"R93-13-20210128","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":". Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results.","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R94-13-20210128","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":". Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R95-13-20210128","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/ATVBAHA.112.248500","article-title":". Role of Src tyrosine kinases in experimental pulmonary hypertension.","volume":"32","author":"Pullamsetti","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R96-13-20210128","doi-asserted-by":"crossref","first-page":"C1709","DOI":"10.1152\/ajpcell.1997.272.5.C1709","article-title":". Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures.","volume":"272","author":"Yu","year":"1997","journal-title":"Am J Physiol Cell Physiol"},{"key":"R97-13-20210128","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":". Altered bone and mineral metabolism in patients receiving imatinib mesylate.","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"R98-13-20210128","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":". Long-term imatinib therapy promotes bone formation in CML patients.","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"R99-13-20210128","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":". Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.","volume":"93","author":"Jonsson","year":"2008","journal-title":"Haematologica"},{"key":"R100-13-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":". Effects of imatinib mesylate in osteoblastogenesis.","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"R101-13-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.988","article-title":". Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.","volume":"30","author":"Tibullo","year":"2012","journal-title":"Hematol Oncol"},{"key":"R102-13-20210128","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":". Imatinib as a potential antiresorptive therapy for bone disease.","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"R103-13-20210128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":". Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R104-13-20210128","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":". Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"key":"R105-13-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","article-title":"PDGF receptors as targets in tumor treatment.","volume":"97","author":"Ostman","year":"2007","journal-title":"Adv Cancer Res"},{"key":"R106-13-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":". Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"R107-13-20210128","first-page":"363","article-title":". Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.","volume":"13","author":"Latagliata","year":"2012","journal-title":"Hematol Oncol"},{"key":"R108-13-20210128","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":". Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R109-13-20210128","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":". Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R110-13-20210128","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":". Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.","volume":"141","author":"De Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"R111-13-20210128","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","article-title":"Distinctive role of the ckit receptor tyrosine kinase signaling in mammalian melanocytes.","volume":"126","author":"Alexeev","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R112-13-20210128","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":". Imatinib mesylate causes hypopigmentation in the skin.","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"R113-13-20210128","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","article-title":"The biology of stem cell factor and its receptor C-kit.","volume":"31","author":"Ashman","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"R114-13-20210128","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":". The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"key":"R115-13-20210128","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3324\/haematol.2012.064618","article-title":". Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.","volume":"97","author":"Neelakantan","year":"2012","journal-title":"Haematologica"},{"key":"R116-13-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":". Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.","volume":"114","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"R117-13-20210128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2010-03-275990","article-title":". Critical role of Src-Syk-PLC2 signaling in megakaryocyte migration and thrombopoiesis.","volume":"116","author":"Mazharian","year":"2010","journal-title":"Blood"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:22:49Z","timestamp":1746084169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201602000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000023","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}